REFERENCES
- Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. Ca: A Cancer Journal for Clinicians 1996; 46: 5–27.
- Roth JA, Putnam SB Jr, Rich TA, Forastiere AA. Cancer of the esophagus. In: De Vita VT Jr, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott, 1997: 980–1021.
- Bleiberg H, Conroy T, Paillot B, et al. Randomized phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33: 1216–20.
- Salts L, Kelson D. Combined modality therapy in the treat-ment of loco-regional oesophageal cancer. Ann Oncol 1992; 3: 793–9.
- Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell car-cinoma of the esophagus: a Japanese esophageal oncology group trial. Jpn J Clin Oncol 1992; 22: 172–6.
- The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.
- Vokes EE, Schilsky RL, Weichselbaum RR, et al. Cisplatin, 5-fluorouracil and high-dose oral leucovorin for advanced head and neck cancer. Cancer 1989; 63: 1048–53.
- Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990; 17: 61–70.
- O'dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: De Vita VT Jr, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology, 5th ed. Philadel-phia: Lippincott, 1997: 418–31.
- Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide cisplatin versus vinblastine bleomycin ± cis-platin cyclophosphamide dactinomycin in patients with good prognosis germ cell tumours. J Clin Oncol 1988; 6: 1231–8.
- Blumenreich MS, Woodcock TM, Jones M, et al. High-dose cisplatin in patients with advanced malignancies. Cancer 1985; 55: 1118–22.
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
- Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Nat Cancer Inst 1994; 86: 1086–91.
- Conroy T, Etienne P-L, Adeni A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal car-cinoma. J Clin Oncol 1996; 14: 164–70.
- Spiridonidis CH, Laufman LR, Jones JJ, Gray DJ, Cho CC, Young DC. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocar-cinoma. Cancer 1996; 77: 2070–7.
- Stahl M, Vahoefer V, Stuschke M, Walz MK, Muller C, Wilke H. Pre-operative sequential chemo-and ra-diochemotherapy in locally advanced carcinomas of the lower esophagus and gastro-oesophageal junction. Eur J Cancer 1998; 34: 668–73.
- Feliu J, Gonzalez BM, Garcia Giron C, et al. Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ coop-erative group, Spain. Am J Clin Oncol 1996; 19: 577–80.